Stocks Health care RGEN
NASDAQ · Health careRepligen Corp (RGEN)
Repligen Corp brought in $805.6M of revenue over the twelve months to September 30, 2026, up 13.8% from a year earlier. It posted a net loss of $11.8M. Operating cash flow minus capital spending left $93.9M of free cash flow in fiscal 2025. At September 30, 2026 it held $727M in cash against $555.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 30, 2026.
Key facts about Repligen Corp
- Net worth
- Repligen Corp has a market value (market cap) of $9.8B at the latest share price, and shareholders' equity of $2.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $738.3M (+16.4% year on year), with net income of $48.9M. Over the 12 months to September 30, 2026: revenue $805.6M, net loss $11.8M.
- Cash flow
- In fiscal 2025 operations brought in $117.4M of cash; after $23.5M of capital spending, free cash flow was $93.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 30, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Repligen Corp's next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Repligen Corp does
Repligen Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker RGEN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $738.3M | $48.9M | $0.86 | $93.9M |
| 2024 | $634.4M | -$25.5M | -$0.46 | $149.7M |
| 2023 | $632.4M | $35.6M | $0.63 | $77.7M |
| 2022 | $801.5M | $186M | $3.24 | $87.2M |
| 2021 | $670.5M | $128.3M | $2.24 | $51.9M |
| 2020 | $366.3M | $59.9M | $1.11 | $40.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RGEN ranks in Health care
Latest SEC filings
What Repligen Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026
- October 30, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 11% to $209.3M versus the same quarter last year; diluted EPS -$0.68 versus $0.26.
- October 30, 2026
- October 27, 2026
- October 7, 2026Passive stake changed SCHEDULE 13G/A
- October 6, 2026Acquisition or sale completed8-KRepligen Corporation completed its acquisition of BioLife Solutions on October 6, 2026.
- September 30, 2026Form 425 filing 425
- September 15, 2026Executive or director change8-KBoard member Karen A. Dawes announced her retirement from the Repligen Corporation Board of Directors effective September 30, 2026.
- September 8, 2026Form 425 filing 425
- September 8, 2026Other event 8-K
What is RGEN worth? A DCF from its reported cash flow
Insider trades
What the people running Repligen Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $6M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 6, 2026 | Douglass Brian RobbCHIEF PRODUCT OFFICER | Received as pay | 700 | - |
| October 5, 2026 | Loeillot OlivierChief Executive Officer, Director | Soldpre-planned (10b5-1) | 1,333 | $238.3K |
| October 5, 2026 | Loeillot OlivierChief Executive Officer, Director | Exercised options | 4,202 | $651.1K |
| October 5, 2026 | Loeillot OlivierChief Executive Officer, Director | Soldpre-planned (10b5-1) | 4,202 | $798.4K |
| October 2, 2026 | Loeillot OlivierChief Executive Officer, Director | Shares withheld for tax | 1,248 | $226.8K |
| September 25, 2026 | Garland Jason KCFO | Shares withheld for tax | 421 | $79.9K |
| September 24, 2026 | Loeillot OlivierChief Executive Officer, Director | Exercised options | 8,404 | $1.3M |
| September 24, 2026 | Loeillot OlivierChief Executive Officer, Director | Soldpre-planned (10b5-1) | 8,404 | $1.6M |
Who owns RGEN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 5.1% | February 5, 2026 |
| Vanguard Capital Management13G, passive | 5% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 480 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 5,384,938 | -608,116 |
| Fmr LLC | 3,326,690 | +439,904 |
| United Capital Financial Advisors, LLC | 2,790,650 | +16,670 |
| Vanguard Capital Management LLC | 2,411,171 | +14,660 |
| Vanguard Portfolio Management LLC | 2,312,825 | +7,731 |
| Maverick Capital Ltd | 1,984,554 | +465,749 |
| State Street Corp | 1,800,530 | +23,245 |
| Massachusetts Financial Services Co | 1,617,021 | +219,506 |
| Wasatch Advisors LP | 1,590,251 | +346,720 |
| Ameriprise Financial Inc | 1,576,132 | +650,918 |
| Bank of New York Mellon Corp | 1,522,859 | -8,543 |
| Invesco Ltd. | 1,387,242 | +108,987 |
| Holocene Advisors, LP | 1,292,191 | +583,302 |
| Rtw Investments, LP | 1,240,637 | +34,637 |
| Geode Capital Management, LLC | 1,062,476 | -1,981 |
| Congress Asset Management Co | 1,012,226 | +214,359 |
| Conestoga Capital Advisors, LLC | 980,983 | -116,800 |
| Goldman Sachs Group Inc | 965,411 | +314,064 |
| Dimensional Fund Advisors LP | 949,863 | +95,122 |
| Stephens Investment Management Group LLC | 937,084 | +181,513 |
Insiders
15 insiders reported holding 376,018 shares in total, about $65.4M at the last price.
| Holder | Shares |
|---|---|
| Dawes Karen ADirector | 92,816 |
| Hunt AnthonyDirector | 89,062 |
| Loeillot OlivierChief Executive Officer, Director | 45,788 |
| Muir Glenn PDirector | 40,051 |
| Bylund JamesChief Operating Officer | 25,423 |
| Kuriyel RalfSenior VP, R&D | 20,062 |
| Garland Jason KCFO | 18,408 |
| Douglass Brian RobbCHIEF PRODUCT OFFICER | 8,685 |
| Madaus Martin DDirector | 6,581 |
| Hughes ViolettaCHIEF ACCOUNTING OFFICER | 6,331 |
Questions about RGEN
What does Repligen Corp do?
Repligen Corp is a company in the Health care sector, listed on NASDAQ as RGEN. Its shares trade on NASDAQ under the ticker RGEN.
What is Repligen Corp's net worth?
Repligen Corp has a market value (market cap) of $9.8B at the latest share price, and shareholders' equity of $2.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Repligen Corp profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $11.8M on revenue of $805.6M.
How much revenue does Repligen Corp make?
Over the twelve months to September 30, 2026 Repligen Corp reported revenue of $805.6M. That is 13.8% more than a year earlier.
When did Repligen Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 30, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the material agreement from November 6, 2026.
When is Repligen Corp's next earnings report?
Repligen Corp's next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RGEN with
Follow RGEN
Get an email when Repligen Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Repligen Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.